share_log

HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $3.75 Price Target

Benzinga ·  Sep 27, 2023 06:42

HC Wainwright & Co. analyst Ed Arce reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $3.75 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment